Pulmonary hemorrhage after percutaneous coronary intervention with abciximab therapy.
Abciximab has a key role in the treatment of patients with acute coronary syndromes undergoing percutaneous coronary intervention; however, an increased risk of bleeding complications is well recognized. We report a case of serious pulmonary hemorrhage after use of abciximab therapy. A definitive indication and treatment guideline should be available to minimize serious bleeding complications. Additionally, respiratory symptoms should be monitored closely for early detection of serious pulmonary hemorrhage in patients receiving abciximab therapy during percutaneous coronary intervention.
Choi
Rak Kyeong
RK
Yoorimbin@hanmail.net
Lee
Nae Hee
NH
Lim
Dal Soo
DS
Hong
Suk keun
Sk
Hwang
Hweung Kon
HK
D000077284:Abciximab; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced* / Q000000981:diagnostic imaging; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects*; D008171:Lung Diseases / Q000139:chemically induced* / Q000000981:diagnostic imaging; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D011859:Radiography
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab